Fu, Siqing http://orcid.org/0000-0002-1933-0419
Piccioni, David E.
Liu, Hongtao
Lukas, Rimas V.
Kesari, Santosh
Aregawi, Dawit
Hong, David S.
Yamaguchi, Kenichiro
Whicher, Kate
Zhang, Yi
Chen, Yu-Luan
Poola, Nagaraju
Eddy, John
Blum, David
Clinical trials referenced in this document:
Documents that mention this clinical trial
A phase I study of the WT2725 dosing emulsion in patients with advanced malignancies
https://doi.org/10.1038/s41598-021-01707-3
Article History
Received: 10 December 2020
Accepted: 19 October 2021
First Online: 16 November 2021
Competing interests
: S.F. and D.A. have nothing to disclose. D.P. is part of the advisory council/committee for AbbVie and Tocagen. H.L. received honoraria from Agios and grants/funds from BMS and Karyopharm. R.L. served on a scientific advisory board for Novocure, Monteris and AbbVie; served on the speakers bureau for Novocure; received consulting fees from AbbVie, American Physician Institute, Medlink Neurology, EBSCO Publishing, Eisai, and New Link Genetics; received a BrainUp grant for Translational Approaches to Brain Tumors; and received research support (drug only) from Bristol Myers Squibb. S.K. is an employee of Pacific Neuroscience Institute, Providence Saint John’s Health Center, John Wayne Cancer Institute; owns stock/shares in Curtana and Nascent; received grants/funds from Aivita, Diffusion, Boston Biomedical, Medicenna, Aadi, BI, Sanofi, Spectrum, Novocure, Northwestern, Orbus Stellar, Prevlar (epicentrx), Stemedica, EORTC-CTCG, EIP Pharma, Caris, Amgen (Omniseq, Guardant, Biocept, LJIAI). D.H. owns stock/shares in OncoResponse Molecular Match (Advisor), OncoResponse (Founder), and Presagia Inc (Advisor); is part of the advisory council/committee and received consulting fees from Alpha Insights, Amgen, Axiom, Adaptimmune, Baxter, Bayer, Genentech, GLG, Group H, Guidepoint, Infinity, Janssen, Merrimack, Medscape, Numab, Pfizer, Prime Oncology, Seattle Genetics, Takeda, Trieza Therapeutics, WebMD; received honoraria from LOXO, miRNA, Genmab, AACR, ASCO, and SITC; received grants/funds from AbbVie, Adaptimmune, Aldi-Norte, Amgen, Astra-Zeneca, Bayer, BMS, Daiichi-Sankyo, Eisai, Fate Therapeutics, Genentech, Genmab, Ignyta, Infinity, Kite, Kyowa, Lilly, LOXO, Merck, Medimmune, Mirati, miRNA, Molecular Templates, Mologen, NCI-CTEP, Novartis, Pfizer, Seattle Genetics, Takeda, Turning Point Therapeutics. K.Y. is an employee of Sumitomo Dainippon Pharma Co., Ltd. K.W., Y.Z., and Y.L.C. are employees of Sunovion Pharmaceuticals Inc. N.P., J.E., and D.B. are former employees of Sunovion Pharmaceuticals Inc. D.B. is a paid consultant of Sunovion Pharmaceuticals Inc.